Cargando…

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Patients with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chemotherapy. An urgent need exists for adjuvant treatments that can enhance or replace current therapeutic options. Here we show the potential of L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Chao, Yu, Mengxia, Ren, Yanling, Li, Kongfei, Maggio, Dominic M., Mei, Chen, Ye, Li, Wei, Juying, Jin, Jie, Zhuang, Zhengping, Tong, Hongyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460144/ https://www.ncbi.nlm.nih.gov/pubmed/28588271 http://dx.doi.org/10.1038/s41598-017-03058-4

Ejemplares similares

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
por: Hu, Chao, et al.
Publicado: (2017)

PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells
por: Ho, Winson S., et al.
Publicado: (2016)

Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma
por: Cui, Jing, et al.
Publicado: (2020)

BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death
por: Stewart, Helen J. S., et al.
Publicado: (2018)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Review of PP2A Tumor Biology and Antitumor Effects of PP2A Inhibitor LB100 in the Nervous System
por: Bryant, Jean-Paul, et al.
Publicado: (2021)

Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.
por: Babudri, N., et al.
Publicado: (1984)

Synthesis and Cytotoxic Evaluation of Arimetamycin A and Its Daunorubicin and Doxorubicin Hybrids
por: Huseman, Eric D., et al.
Publicado: (2021)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target
por: Li, Kongfei, et al.
Publicado: (2014)

Adipocyte metabolism of the chemotherapy daunorubicin
por: Mittelman, Steven D., et al.
Publicado: (2018)

Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair
por: Lv, Peng, et al.
Publicado: (2014)

Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia
por: Al-Aamri, Hussain Mubarak, et al.
Publicado: (2019)

Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine
por: Hwang, Yu-Yan, et al.
Publicado: (2012)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.
por: Sehested, M., et al.
Publicado: (1987)

Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007)

Interactions of Cisplatin and Daunorubicin at the Chromatin Level
por: Firouzi Niaki, Erfaneh, et al.
Publicado: (2020)

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin
por: Han, Yixiang, et al.
Publicado: (2015)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
por: Liu, Fu-rong, et al.
Publicado: (2017)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

Cardiolipin for Enhanced Cellular Uptake and Cytotoxicity of Thermosensitive Liposome-Encapsulated Daunorubicin toward Breast Cancer Cell Lines
por: Alrbyawi, Hamad, et al.
Publicado: (2022)

HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling
por: Yang, Shuo, et al.
Publicado: (2019)

TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling
por: Xiao, Yi, et al.
Publicado: (2020)

DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias
por: Boulanger, Mathias, et al.
Publicado: (2023)

Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia
por: Huang, Xiaomeng, et al.
Publicado: (2016)

Purvalanol A, Olomoucine II and Roscovitine Inhibit ABCB1 Transporter and Synergistically Potentiate Cytotoxic Effects of Daunorubicin In Vitro
por: Cihalova, Daniela, et al.
Publicado: (2013)

Cytotoxic Effects of Vitamin A in Combination with Vincristine, Daunorubicin and 6‐Thioguanine upon Cells from Lymphoblastic Leukemic Patients
por: Pieters, Rob, et al.
Publicado: (1991)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
por: Burnett, A K, et al.
Publicado: (2017)

Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin
por: Rai, Yogesh, et al.
Publicado: (2019)

MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin
por: Bollaert, Emeline, et al.
Publicado: (2021)

Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth
por: Shuhaibar, Leia C., et al.
Publicado: (2021)

PB2396: HDACI COMBINED WITH LB100 PROMOTES THE OCCURRENCE OF FERROZOSIS IN CTCL
por: Shi, Wenyu
Publicado: (2023)

Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia
por: Bai, Jin, et al.
Publicado: (2012)

High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia
por: Li, Kongfei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mu8viprfqkomsnsc70p0jjffk4